TABLE 2.
Relative ND50s of human sera for parental and chimeric SF162/JR-FL Env pseudotypes
| Human serum | ND50 for pseudotypea:
|
|||
|---|---|---|---|---|
| SF162 | JR(SF V1/V2) | JR-FL | SF(JR V1/V2) | |
| 2 | 90,000 | 115,000 | <20 | <20 |
| 4 | 43,000 | 75,000 | <20 | 120 |
| 25 | 31,000 | 13,000 | <20 | <20 |
| 16 | 25,000 | 16,000 | <20 | <20 |
| 04-2594k | 14,000 | 10,800 | <20 | <20 |
| 26 | 14,000 | 10,500 | <20 | 40 |
| 04-2435j | 13,500 | 8,500 | <20 | <20 |
| 04-1642F | 12,800 | 32,000 | <20 | <20 |
| 04-8942K | 12,200 | 13,500 | <20 | 20 |
| 9 | 11,000 | 11,800 | <20 | 20 |
| 04-2416d | 9,000 | 13,600 | <20 | <20 |
| 6 | 51,000 | 36,000 | 130 | 1,500 |
| 04-1360c | 27,000 | 36,000 | 95 | 140 |
| 04-3058c | 10,000 | 16,800 | 60 | 270 |
| 3 | 11,500 | 12,800 | 80 | 140 |
| 04-3062c | 9,500 | 8,700 | 90 | 150 |
| 17 | 12,700 | 9,100 | 140 | 1,480 |
| 04-1657F | 71,000 | 66,000 | 930 | 5,700 |
| 04-2132E | 75,000 | 93,000 | 1,300 | 3,000 |
| 21 | 10,500 | 29,000 | 180 | 1,100 |
| 04-0748D | 48,000 | 48,000 | 1,150 | 5,500 |
| 10 | 6,500 | 13,000 | 160 | 135 |
| 04-2213c | 6,700 | 12,000 | 180 | 1,000 |
| 22 | 10,000 | 14,000 | 400 | 1,000 |
| 04-0405J | 90,000 | 120,000 | 4,000 | 700 |
| 04-03552A | 12,800 | 97,000 | 1,400 | 5,300 |
| 18a | 7,500 | 29,000 | 1,100 | 2,900 |
| 04-2583b | 52,000 | 78,000 | 12,000 | 58,000 |
| NHSb | <20 | <20 | <20 | <20 |
a
ND50s correspond to dilutions required to reduce luc activity by 50%.
b
NHS, normal human sera (a pool of 9 normal sera tested as a control).